DiaMedica Therapeutics Inc. Operating Expenses
DiaMedica Therapeutics Inc. (DMAC) reported Operating Expenses of $34.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-03-30
- DiaMedica Therapeutics Inc. operating expenses for the quarter ending 2019-03-31 was $3.42M, a 161.94% increase year-over-year.
- DiaMedica Therapeutics Inc. operating expenses for the quarter ending 2018-03-31 was $1.31M.
- DiaMedica Therapeutics Inc. operating expenses for fiscal 2025 was $34.40M, a 28.92% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. operating expenses for fiscal 2024 was $26.68M, a 25.46% increase from fiscal 2023.
- DiaMedica Therapeutics Inc. operating expenses for fiscal 2023 was $21.27M, a 51.90% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. operating expenses for fiscal 2022 was $14.00M, a 2.60% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 12 month |
|---|---|---|
| 2025-12-31 | $34.40M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $26.68M 10-K · filed 2026-03-30 | |
| 2023-12-31 | $21.27M 10-K · filed 2025-03-17 | |
| 2022-12-31 | $14.00M 10-K · filed 2024-03-19 | |
| 2021-12-31 | $13.65M 10-K · filed 2023-03-28 | |
| 2020-12-31 | $12.70M 10-K · filed 2022-03-14 | |
| 2019-12-31 | $11.59M 10-K · filed 2021-03-10 | |
| 2019-03-31 | $3.42M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $7.26M 10-K · filed 2020-03-23 | |
| 2018-03-31 | $1.31M 10-Q · filed 2019-05-13 | |
| 2017-12-31 | $4.52M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |